FDA Grants RMAT Designation to RZ-001, a Novel RNA Therapy for Hepatocellular Carcinoma

Rznomics announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation to RZ-001, its lead investigational RNA-based gene therapeutic candidate for hepatocellular carcinoma. The designation was supported by promising Phase 1b/2a clinical data, including a favorable safety profile and preliminary response signals in a disease that continues to carry substantial unmet need despite recent advances in systemic therapy.

RMAT designation is intended to accelerate the development and review of regenerative medicine products, including gene therapies, for serious or life-threatening diseases. To qualify, a therapy must show preliminary clinical evidence suggesting that it has the potential to address unmet medical needs. The designation can provide sponsors with closer FDA interaction, guidance on clinical development and manufacturing, and potential eligibility for priority review, rolling review, and accelerated approval pathways.

RZ-001 is based on Rznomics’ proprietary trans-splicing ribozyme technology platform. The approach is designed to replace cancer-specific RNA with therapeutic RNA, creating a tumor-selective mechanism that may help limit toxicity while targeting malignant cells. Rznomics describes the candidate as a next-generation oncology therapy intended to overcome some limitations of conventional treatment strategies in HCC.

The company has already received several regulatory designations for RZ-001 in this indication. The therapy was granted Orphan Drug Designation in 2024 and Fast Track Designation in 2025 for the treatment of hepatocellular carcinoma. The new RMAT status adds another regulatory mechanism that could support a more structured and accelerated development pathway in the United States.

"Receiving RMAT designation for RZ-001 is a profound validation of the innovation and competitiveness of our RNA editing platform by the FDA. We will concentrate our resources on global development and commercialization to provide a breakthrough therapeutic option in the field of HCC, where unmet medical needs remain exceptionally high," said Seong-Wook Lee, CEO of Rznomics.